Company Overview and News

2
Gritstone Oncology Prepares Final Terms For IPO

11h seekingalpha
Gritstone Oncology intends to raise $85 million from the sale of its common stock in an IPO.
BLUE BLUE

65
Bluebird Bio Stock May Have Upside of at Least 60 Percent

2018-09-13 investorplace - 3
Just as Bluebird Bio (NASDAQ:BLUE) started gaining traction in the markets in August, the stock erased all those gains since the start of September. And the month is hardly over. Why did BLUE stock fall 12% last week when the company did not issue any news that would explain what changed, fundamentally?
REGN BLUE DRNA IBB GBT

6
BLUE / bluebird bio, Inc. 8-K (Current Report)

2018-09-11 sec.gov - 4
blue-8k_20180911.htm
BLUE

5
Amgen Looks To Enter Multiple Myeloma Space: Can It Compete?

2018-09-11 seekingalpha - 1
Amgen announces positive preliminary results using its antibody drug known as AMG 420, which is derived from the anti-BCMA BiTE program.
AMGN BLUE CELG BLUE

9
bluebird (BLUE) Reports Updated Data on Lenti-D Gene Therapy

2018-09-06 zacks
bluebird bio, Inc. (BLUE - Free Report) announced updated results from phase II/III Starbeam study (ALD-102) of its investigational Lenti-D gene therapy in boys aged 17 years or below with cerebral adrenoleukodystrophy (CALD). The company also announced initial results from the ongoing observational ALD-103 study of outcomes from allogeneic hematopoietic stem cell transplant (allo-HSCT) in boys aged 17 years or below with CALD.
CELGZ GILD BLUE LGNDZ TJX LGNZZ CELG LGND KHC LGNYZ LGNXZ BLUE

3
BLUE / bluebird bio, Inc. 8-K (Current Report)

2018-09-05 sec.gov - 1
blue-8k_20180905.htm
BLUE

14
Software and Biotech Are Eating the World

2018-08-30 zacks - 1
There is no doubt that software stocks are on fire, igniting new highs for the stock market. And if the valuations were untouchable a year ago, they are definitely too hot to handle now.
WFC WFCNP SQ ULH BLUE CRSP NVDA SCVL BLUE BOOT

21
Play The Future of Gene Therapy With These 5 Biotech Stocks

2018-08-27 investorplace
Innovation has always been the mantra when it comes to biotech stocks. And as such, the biotech sector has been the key driver for new medicines and therapies over the last decade or so. But we haven’t seen anything like this before. Gene therapy is quickly becoming the technique du jour for curing orphan and rare diseases.
NITE REGN GILD QURE CELG SRPT KITE BLUE

2
IPO Biotech Preview: Gritstone Oncology

2018-08-27 seekingalpha
Gritstone Oncology is gearing up for its $80 million IPO, and its prospects are highly promising.
BLUE BLUE

15
Nightstar Therapeutics: Keep Your Eyes Peeled For September Catalysts

2018-08-27 seekingalpha
Nightstar Therapeutics is a clinical-stage biotechnology company developing gene therapies for the treatment of currently untreatable retinal diseases.
NITE SRPT BLUE ONCE

13
Your Cancer Research Highlight: Bristol-Myers Looks For An In To Earlier Multiple Myeloma

2018-08-24 seekingalpha
Bristol-Myers has finally gotten out a new application for approval for its relatively small Empliciti franchise.
AMGN BLUE CELG ABBV BLUE ABBV

9
Alexandria Inks First Lease for 1818 Fairview Development

2018-08-23 zacks
Alexandria Real Estate Equities Inc. (ARE - Free Report) has bagged its first tenant at the 1818 Fairview development project — a four-story life-science office building located in the Lake Union submarket — per an article citing Jesse Ottele, Newmark Knight Frank’s real estate broker.
SOJA ARE SO STZ.B STZ PSB JLL WPC BLUE

4
BLUE / bluebird bio, Inc. 8-K (Current Report)

2018-08-23 sec.gov - 2
blue-8k_20180823.htm
BLUE

12
bluebird bio: Heading To $200 On Pipeline Progress And Potential M&A

2018-08-22 seekingalpha - 1
bluebird bio is a clinical-stage biotechnology company focussed on gene therapy, cancer immunopathy and gene editing for the treatment of cancer and rare diseases.
MBIO REGN GILD JUNO BLUE CELG NVS KITE BLUE CR

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to BLUE / bluebird bio, Inc. on message board site Silicon Investor.

Daily Bluegrass Daily Bluegrass Daily Bluegrass Blue Eyes Crying in the Rain Blue Eyes Crying in the Rain Blue Eyes Crying in the Rain
bluebird bio Inc. bluebird bio Inc. bluebird bio Inc. Blueprint Medicines Blueprint Medicines Blueprint Medicines
BTV.V - Bluerush Media Group BTV.V - Bluerush Media Group BTV.V - Bluerush Media Group Blue Coat Inc. Blue Coat Inc. Blue Coat Inc.
Blue Chip Gold Stocks HM, NEM, ASA, ABX, PDG Blue Chip Gold Stocks HM, NEM, ASA, ABX, PDG Blue Chip Gold Stocks HM, NEM, ASA, ABX, PDG Blue Water Global Group Inc. Blue Water Global Group Inc. Blue Water Global Group Inc.
MIDNIGHT BLUES CAFE MIDNIGHT BLUES CAFE MIDNIGHT BLUES CAFE Blue Chip Gold Stocks HM, NEM, ASA, ABX, PDG (MODERATED) Blue Chip Gold Stocks HM, NEM, ASA, ABX, PDG (MODERATED) Blue Chip Gold Stocks HM, NEM, ASA, ABX, PDG (MODERATED)
CUSIP: 09609G100